

## **AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions and listings of the claims in the application.

1-190. (Canceled)

191. (Previously presented) A purified peptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 25-33.

192. (Previously presented) A purified chimeric peptide comprising at least two peptides consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 25-33, wherein said peptides are in covalent linkage.

193-221. (Canceled)

222. (Previously presented) The purified peptide of claim 191, wherein said amino acid sequence is selected from the group consisting of SEQ ID NOs: 25, 28 and 30.

223. (Previously presented) The purified peptide of claim 191, wherein said peptide is chemically synthesized.

224. (Previously presented) The purified peptide of claim 191, wherein said peptide is recombinantly synthesized.

225. (Previously presented) The purified peptide of claim 191, wherein said peptide is provided as a degradation product.

226. (Previously presented) The purified peptide of claim 222, wherein said amino acid sequence is SEQ ID NO:25.

227. (Previously presented) The purified peptide of claim 222, wherein said amino acid sequence is SEQ ID NO:28.

228. (Previously presented) The purified peptide of claim 222, wherein said amino acid sequence is SEQ ID NO:30.

229. (Previously presented) The purified peptide of claim 222, wherein said amino acid sequence is SEQ ID NO:28.

230. (Previously presented) The purified peptide of claim 192, wherein at least one of said peptides consists of an amino acid sequence selected from the group consisting of SEQ ID NOs: 25, 28 and 30.

231. (Previously presented) The purified peptide of claim 230, wherein said amino acid sequence is SEQ ID NO:25.

232. (Previously presented) The purified peptide of claim 230, wherein said amino acid sequence is SEQ ID NO:28.

233. (Previously presented) The purified peptide of claim 230, wherein said amino acid sequence is SEQ ID NO:30.

234. (Previously presented) The purified chimeric peptide of claim 192, comprising at least two peptides selected from the group consisting of SEQ ID NOs: 25, 28 and 30.

235. (Previously presented) The purified peptide of claim 192, wherein at least one of said peptides is chemically synthesized.

236. (Previously presented) The purified peptide of claim 235, wherein said peptides are chemically synthesized.

237. (Previously presented) The purified peptide of claim 192, wherein at least one of said peptides is recombinantly synthesized.

238. (Previously presented) The purified peptide of claim 191, wherein at least one said peptides is provided as a degradation product.

239. (Previously presented) A purified chimeric peptide consisting of two covalently linked peptides, wherein at least one of said peptides consists of an amino acid selected from the group consisting of SEQ ID NOs: 25-33, and wherein said peptides are chemically synthesized.

240. (New) A purified peptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 34-4000.

241. (New) A pharmaceutical composition comprising as an active ingredient a peptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 27-4000 and a pharmaceutically acceptable carrier.

242. (New) A method of preventing or treating an autoimmune or infectious disease or condition, the method comprising administering to a subject in need thereof a therapeutically effective amount of a peptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 27-4000.

243. (New) The method of claim 242, wherein said autoimmune or infectious disease or condition is selected from the group consisting of a viral disease, a viral infection, AIDS, and infection by HIV.
244. (New) A method of preventing or treating a blood disease or condition, the method comprising administering to a subject in need thereof a therapeutically effective amount of a peptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 27-4000.
245. (New) The method of claim 244, wherein said blood disease or condition is selected from the group consisting of thrombocytopenia, pancytopenia, granulocytopenia, an erythropoietin treatable condition, and a thrombopoietin treatable condition.
246. (New) The method of claim 244, further comprising administering to said subject in need thereof an effective amount of a blood cell stimulating factor, said blood cell stimulating factor selected from the group consisting of thrombopoietin, erythropoietin and granulocyte colony stimulating factor (G-CSF).
247. (New) A method of modulating blood cell formation, the method comprising administering to a subject in need thereof a therapeutically effective amount of a peptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 27-4000.
248. (New) The method of claim 247, wherein said modulating blood cell formation is selected from the group consisting of inducing hematopoiesis, inducing hematopoietic stem cells proliferation, inducing hematopoietic stem cells proliferation and differentiation, inducing megakaryocytopoiesis, inducing erythropoiesis, inducing leukocytopoiesis, inducing thrombocytopoiesis, inducing

plasma cell proliferation, inducing dendritic cell proliferation and inducing macrophage proliferation.

249. (New) The method of claim 247, further comprising administering to said subject in need thereof an effective amount of a blood cell stimulating factor, said blood cell stimulating factor selected from the group consisting of thrombopoietin, erythropoietin and granulocyte colony stimulating factor (G-CSF).
250. (New) A method of enhancing peripheral stem cell mobilization, the method comprising administering to a subject in need thereof a therapeutically effective amount of a peptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 27-4000.
251. (New) The method of claim 250, further comprising administering to said subject in need thereof an effective amount of a blood cell stimulating factor, said blood cell stimulating factor selected from the group consisting of thrombopoietin, erythropoietin and granulocyte colony stimulating factor (G-CSF).
252. (New) A method of preventing or treating a metabolic disease or condition, the method comprising administering to a subject in need thereof a therapeutically effective amount of a peptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 27-4000.
253. (New) The method of claim 252, wherein said metabolic disease or condition is selected from the group consisting of NIDDM, IDDM, glucosuria, hyperglycemia, hyperlipidemia, and hypercholesterolemia.
254. (New) A method of preventing or treating conditions associated with myeloablative doses of chemoradiotherapy supported by autologous bone marrow

or peripheral blood stem cell transplantation (ASCT) or allogeneic bone marrow transplantation (BMT), the method comprising administering to a subject in need thereof a therapeutically effective amount of a peptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 27-4000.

255. (New) The method of claim 254, further comprising administering to said subject in need thereof an effective amount of a blood cell stimulating factor, said blood cell stimulating factor selected from the group consisting of thrombopoietin, erythropoietin and granulocyte colony stimulating factor (G-CSF).
256. (New) A method of augmenting the effect of a blood cell stimulating factor, the method comprising administering to a subject in need thereof a therapeutically effective amount of a peptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 27-4000.
257. (New) The method of claim 256, wherein said blood cell stimulating factor is selected from the group consisting of thrombopoietin, erythropoietin and granulocyte colony stimulating factor (G-CSF).
258. (New) A method of enhancing colonization of donated blood stem cells in a myeloablated recipient, the method comprising treating a donor of said donated blood stem cells with a therapeutically effective amount of peptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 27-4000 prior to donation and implanting the donated blood stem cells in the recipient.
259. (New) The method of claim 258, further comprising treating said donor with a blood cell stimulating factor, said blood cell stimulating factor selected from the group consisting of thrombopoietin, erythropoietin and granulocyte

colony stimulating factor (G-CSF) prior to donation and implanting the blood stem cells in the recipient.

260. (New) A method of enhancing colonization of donated blood stem cells in a myeloablated recipient, the method comprising treating said donated blood stem cells with a therapeutically effective amount of peptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 27-4000 prior to implanting the donated blood stem cells in the recipient.

261. (New) The method of claim 260, further comprising treating said donated blood cells with a blood cell stimulating factor, said blood cell stimulating factor selected from the group consisting of thrombopoietin, erythropoietin and granulocyte colony stimulating factor (G-CSF) prior to implanting the blood stem cells in the recipient.

262. (New) A method of enhancing colonization of blood stem cells in a myeloablated recipient, the method comprising treating said blood stem cells with a peptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 27-4000 prior to implanting the blood stem cells in the recipient.

263. (New) The method of claim 262, further comprising treating said blood stem cells with a blood cell stimulating factor, said blood cell stimulating factor selected from the group consisting of thrombopoietin, erythropoietin and granulocyte colony stimulating factor (G-CSF) prior to implanting the blood stem cells in the recipient.

264. (New) A method for preventing or treating a condition associated with a SARS infective agent, the method comprising administering to a subject in need